NEW YORK, Jan. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Turkey, a 'pharmerging' market, has evolved to this status after a series of economic and healthcare reforms. The country was at the verge of financial collapse until 2001 with inflation running in near three digits. However, the economic reforms implemented by the country have turned it into a dynamic economy. The country's pharmaceutical industry has been a frontrunner in these reforms. Turkey has a growing pharmaceutical sector with around 300 pharmaceutical companies selling up to 1.3bn units of products every year. Factors that have fuelled the growth of the pharmaceutical industry in the country include economic growth, high healthcare expenditures, a young workforce and a host of companies delivering drugs to the populace.
The reforms taken up by the country made the healthcare system more efficient, improving access for the population, besides bringing the system in sync with the standards of other EU nations. At the same time, the country's growing economic consistency brought in foreign investment in the sector and bolstered consumer spending on pharmaceuticals. The healthcare reforms taken up by the country included implementation of a patent legislation in 1995, creation of a generics registration law in 1996 and establishment of a reference pricing system in 2004. However, the industry continues to have some problems still, such as a protracted product registration system and a reimbursement list that is deemed incomplete and biased.
Key features of this report
- Epidemiological analysis of the major diseases and forecast prevalence of the common diseases over the period 2008-14 .
- Macroeconomic analysis of the country with a special focus on the healthcare sector reforms and its impact analysis.
- An overview of the IPR climate, the recent amendments and current state of pharmaceutical innovation.
- Detailed analysis of the leading therapeutic categories and classes including forecast sales over the period 2008-2014 and a review of the leading brands in each.
Scope of this report
- Develop an understanding of the Turkish healthcare system and the issues facing it.
- Understand the IP laws in Turkey and how they affect the pharmaceutical R&D pipeline.
- Understand how the companies are altering their strategies and adopting new business models to sustain profitable growth in the new political and economic climate.
- Gain up-to-date competitive intelligence and understand the major issues affecting the pharmaceutical major.
- Compare the franchises of top pharmaceutical players across major indications, and understand how market share of leading companies will change over the next six years.
Key Market Issues
- Targeting niche therapeutic segments and overseas expansion
Although Turkish companies have prospered in recent years, intense generic competition and regulatory hurdles have forced many local manufacturers to look for niche products and overseas markets to expand and drive future revenue growth.
- Few local manufacturers with FDA approved sites
Even though, Turkey has a large number of local manufacturers, only few of them have FDA approved production sites. For example, Mustafa Nevzat, one of the few FDA approved companies for finished products, is developing a production facility for oncology drugs which could export drugs to the US in the near future.
- A lengthy reimbursement review process
In Turkey, the average time a medicine spends in reimbursement review is over 225 days, which is much above the optimum time of 90 days. Besides, usage of generics is encouraged and so specialized therapeutics that have no generic equivalents seem to suffer.
Key findings from this report
- Turkey's Ministry of Health (MoH) was one of the first state run bodies in the world to focus on disease prevention and not just treatment. MoH still remains the only body in the country that provides preventative healthcare services, besides being a key provider of primary and secondary care.
- Over the recent past, Turkey has been improving its healthcare services by importing large quantities of modern machinery and equipment to improve the healthcare services in hospitals. In 2006 the MoH initiated a project to build medical centers in three major cities. The government has also been encouraging multinational companies to invest in the country's healthcare industry.
Key questions answered
- How is the regulatory set up of the Turkish pharmaceutical market?
- How does the Turkish pharmaceutical market compare with other emerging pharmaceutical markets?
- What will be the major growth drivers in the Turkish pharmaceutical market over the period 2008-14?
- Which companies were leading in the Turkish pharmaceutical market in 2008?
- What are the key relative strengths of the leading companies?
Table of Contents
The Turkish Pharmaceutical Market Outlook to 2014
Executive Summary 10
Turkey – an overview 10
Turkey – healthcare system and regulation 11
Turkish pharmaceutical market 12
Competitive landscape 13
Scope and methodology 15
Chapter 1 Turkey – an overview 18
The government 19
The economy 20
Key economic parameters 21
Population profile and demographic trends 22
Disease burden 22
Forecast epidemiology 24
Chapter 2 Turkey – healthcare system and regulation 28
Key recent events 29
Prescription regulation suspended 29
Furthering the healthcare reforms agenda 30
A snapshot of the healthcare reforms in the country 30
Turkey healthcare system 31
Financing healthcare 34
Health insurance 34
Healthcare expenditure 37
Drug regulation 37
Intellectual property rights 37
Securing a marketing authorization 38
Drug pricing 41
Pharmaceutical distribution channels 41
Chapter 3 Turkish pharmaceutical market 44
Key recent issues 45
The Turkish government's planned price reforms may adversely affect pharmaceutical growth 45
Key recent events 46
Zentiva acquired a majority stake in Eczacibasi's pharmaceutical and fine chemicals division 46
Daiichi Sankyo focuses on acquisition-driven growth in Turkey 46
Pharming and Aslan Group signed a licensing agreement for lactoferrin 46
Vical licenses melanoma drug Allovectin-7 to Eczacibasi 47
Therapy area analysis 47
Therapy area sales forecast 2008–14 55
Leading brands 56
Leading brands sales forecast 58
Generic pharmaceutical market in Turkey 58
Performance of generics across therapy areas 63
Leading generic products 65
Chapter 4 Competitive landscape 68
Competitive positioning of the leading players in the Turkish pharma market 70
Detailed analysis of major foreign pharmaceutical players in Turkey 72
Sales focus by leading drug class 72
Marketed product portfolio 74
Novartis' pipeline focus 77
Strategic growth analysis 78
Sales focus by leading drug class 81
Marketed product portfolio 82
Sanofi-Aventis pipeline focus 84
Strategic growth analysis 85
Sales focus by leading drug class 87
Marketed product portfolio 89
Pfizer's pipeline focus 91
Strategic growth analysis 93
Sales focus by leading drug class 95
Marketed product portfolio 97
GSK's pipeline focus 99
Strategic growth analysis 100
Detailed analysis of key domestic pharmaceutical players in Turkey 102
Sales focus by leading drug class 102
Marketed product portfolio 104
Ibrahim's pipeline focus 105
Strategic growth analysis 106
Sales focus by leading drug class 107
Marketed product portfolio 109
Bilim's pipeline focus 110
Strategic growth analysis 110
Competitive positioning of leading generic players in Turkey 111
Chapter 5 Appendix 114
Anatomical therapeutic classification (ATC) 114
A: Alimentary tract and metabolism 114
B: Blood and blood-forming organs 114
C: Cardiovascular system 114
D: Dermatologicals 115
G: Genitourinary system and sex hormones 115
H: Systemic hormonal preparations 115
J: General anti-infectives systemic 115
K: Hospital solutions 115
L: Antineoplastic and immunomodulating agents 115
M: Musculoskeletal system 116
N: Nervous system 116
P: Parasitology 116
R: Respiratory system 116
S: Sensory organs 116
T: Diagnostic agents 116
V: Various 116
Forecast factors 117
List of Figures
Figure 1.1: Percentage change in deaths by disease category in Turkey, 2000–05 24
Figure 2.2: Organization of the Turkish healthcare system 33
Figure 3.3: Top 10 drug classes of the anti-infective therapy area ($m), 2008 49
Figure 3.4: Top 10 drug classes of the alimentary tract and metabolism therapy area ($m), 2008 50
Figure 3.5: Top 10 drug classes of the cardiovascular system therapy area ($m), 2008 51
Figure 3.6: Top 10 drug classes of the nervous system therapy area ($m), 2008 52
Figure 3.7: Top 10 drug classes of the respiratory system therapy area ($m), 2008 53
Figure 3.8: Growth analysis of therapy areas in Turkey, 2007–08 54
Figure 3.9: Comparative performance of generic and branded market segments in Turkey, 2007– 08 61
Figure 3.10: Comparative performance of generic and branded market segments in Turkey and 7MM, 2007–08 62
Figure 3.11: Growth analysis of therapy areas in the Turkish generic market Turkey, 2008 64
Figure 4.12: Top 10 companies positioning in Turkey based on prescription sales, 2008 71
Figure 4.13: Novartis' Turkish pharmaceutical market sales by therapy area, 2008 73
Figure 4.14: Sanofi-Aventis' Turkish pharmaceutical market sales by therapy area, 2008 82
Figure 4.15: Pfizer's Turkish pharmaceutical market sales by therapy area, 2008 88
Figure 4.16: GSK's Turkish pharmaceutical market sales by therapy area, 2008 96
Figure 4.17: Ibrahim's Turkish pharmaceutical market sales by therapy area, 2008 103
Figure 4.18: Bilim's Turkish pharmaceutical market sales by therapy area, 2008 108
Figure 4.19: Positioning of top 10 generic players in Turkey, 2008 112
List of Tables
Table 1.1: Key political parameters of Turkey 20
Table 1.2: Key economic parameters of Turkey 21
Table 1.3: Key demographic parameters of Turkey 22
Table 1.4: Forecast epidemiology of common risk factors in Turkey, 2008–14 25
Table 2.5: Comparison of key healthcare system parameters of Turkey with OECD average 33
Table 2.6: Biosimilar products registered in EU till June 2009 41
Table 3.7: Turkey pharmaceutical market by therapy area sales, 2008 48
Table 3.8: Turkish pharmaceutical market therapy area sales forecast ($m), 2008–14 55
Table 3.9: Turkish pharmaceutical market by leading brands, 2008 56
Table 3.10: Top 10 brands of the Turkish pharmaceutical market, sales forecast 2008–14 58
Table 3.11: Generic pharmaceutical market in Turkey, 2008 60
Table 3.12: Generic pharmaceutical sales across therapy areas, 2008 63
Table 3.13: Top 10 generic products in Turkey, 2008 65
Table 4.14: Leading companies in the Turkish pharmaceutical market based on prescription sales, 2008 70
Table 4.15: Novartis' leading brands in the Turkish pharmaceutical market, 2008 75
Table 4.16: Sanofi-Aventis' leading brands in the Turkish pharmaceutical market, 2008 83
Table 4.17: Pfizer's leading brands in the Turkish pharmaceutical market, 2008 89
Table 4.18: GSK's leading brands in the Turkish pharmaceutical market, 2008 97
Table 4.19: Ibrahim's leading brands in the Turkish pharmaceutical market, 2008 104
Table 4.20: Bilim's leading brands in the Turkish pharmaceutical market, 2008 109
Table 4.21: Leading generic players in the Turkish pharmaceutical market, 2008 113
To order this report:
Intl: +1 805-652-2626